185.91
4.46 (2.46%)
| Previous Close | 181.45 |
| Open | 178.36 |
| Volume | 2,218,362 |
| Avg. Volume (3M) | 2,014,147 |
| Market Cap | 30,560,231,424 |
| Price / Earnings (TTM) | 36.24 |
| Price / Earnings (Forward) | 21.05 |
| Price / Sales | 9.90 |
| Price / Book | 4.25 |
| 52 Weeks Range | |
| Earnings Date | 4 Mar 2026 |
| Profit Margin | 27.34% |
| Operating Margin (TTM) | 30.79% |
| Diluted EPS (TTM) | 4.70 |
| Quarterly Revenue Growth (YOY) | 16.70% |
| Quarterly Earnings Growth (YOY) | 41.20% |
| Total Debt/Equity (MRQ) | 1.24% |
| Current Ratio (MRQ) | 4.61 |
| Operating Cash Flow (TTM) | 1.20 B |
| Levered Free Cash Flow (TTM) | 1.05 B |
| Return on Assets (TTM) | 6.90% |
| Return on Equity (TTM) | 14.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Veeva Systems Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -4.0 |
| Average | -0.63 |
|
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company’s best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Mid Growth |
| % Held by Insiders | 8.55% |
| % Held by Institutions | 86.32% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 296.00 (JP Morgan, 59.22%) | Buy |
| Median | 260.00 (39.85%) | |
| Low | 212.00 (Stifel, 14.03%) | Buy |
| Average | 253.80 (36.52%) | |
| Total | 7 Buy, 3 Hold | |
| Avg. Price @ Call | 183.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 05 Mar 2026 | 240.00 (29.09%) | Hold | 185.91 |
| Morgan Stanley | 05 Mar 2026 | 215.00 (15.65%) | Hold | 185.91 |
| 17 Feb 2026 | 205.00 (10.27%) | Hold | 176.82 | |
| Needham | 05 Mar 2026 | 270.00 (45.23%) | Buy | 185.91 |
| Piper Sandler | 05 Mar 2026 | 285.00 (53.30%) | Buy | 185.91 |
| RBC Capital | 05 Mar 2026 | 275.00 (47.92%) | Buy | 185.91 |
| UBS | 05 Mar 2026 | 220.00 (18.34%) | Hold | 185.91 |
| 20 Feb 2026 | 200.00 (7.58%) | Hold | 180.31 | |
| Stifel | 26 Feb 2026 | 212.00 (14.03%) | Buy | 182.86 |
| Barclays | 25 Feb 2026 | 250.00 (34.47%) | Buy | 176.46 |
| Oppenheimer | 24 Feb 2026 | 275.00 (47.92%) | Buy | 175.79 |
| JP Morgan | 20 Feb 2026 | 296.00 (59.22%) | Buy | 180.31 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | 13 of the Top 20 Biopharmas Standardize Globally on Veeva Link Key People |
| 29 Jan 2026 | Announcement | Veeva Announces eSource Application for Research Sites to Eliminate Paper and Streamline Clinical Trial Data Flow |
| 27 Jan 2026 | Announcement | Industry Research Finds Establishing a Foundation for AI is Top Priority for CPG Enterprises |
| 08 Jan 2026 | Announcement | Veeva to Present at the J.P. Morgan 2026 Healthcare Conference |
| 08 Jan 2026 | Announcement | Veeva and BioMarin Form Long-Term Strategic Partnership |
| 08 Jan 2026 | Announcement | Veeva Announces Environmental Monitoring Solution to Modernize Quality Control in Manufacturing |
| 07 Jan 2026 | Announcement | Novo Nordisk International Operations Commits to Veeva Vault CRM |
| 05 Jan 2026 | Announcement | Veeva Announces Share Repurchase Program |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |